| Trial ID: | L4484 |
| Source ID: | NCT01536613
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Post Marketing Surveillance Study of Biphasic Insulin Aspart 30
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: Change in body weight | Secondary: Change in fasting plasma glucose (FPG)|Change in HbA1c (glycosylated haemoglobin)|Occurrence of adverse events (non-serious and serious)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
5346
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2004-09
|
| Completion Date: |
2007-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-03-07
|
| Locations: |
Seoul, 137-920, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01536613
|
